真性红细胞增多症患者静脉血栓栓塞后二级预防的最佳策略是什么？ - Suppr

What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?

作者信息

Ajufo Helen, Vaughn Jennifer

机构信息

Memorial Sloan Kettering Cancer Center, New York, NY.

Division of Hematology, The Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH.

出版信息

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):547-550. doi: 10.1182/hematology.2024000674.

DOI:10.1182/hematology.2024000674

PMID:39644039

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11665551/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2720/11665551/e34beac99f4f/hem.2024000674_s1.jpg

相似文献

What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?

Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):547-550. doi: 10.1182/hematology.2024000674.

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.

Haematologica. 2008 Mar;93(3):372-80. doi: 10.3324/haematol.12053. Epub 2008 Feb 11.

[Analysis of risk factors for venous thromboembolism in patients with polycythemia vera and establishment of a prediction model].

Zhonghua Yi Xue Za Zhi. 2024 Jul 2;104(25):2336-2341. doi: 10.3760/cma.j.cn112137-20240304-00476.

Thromboembolic complications of polycythemia: polycythemia vera versus smokers' polycythemia.

J Vasc Surg. 1993 Mar;17(3):518-22; discussion 522-3.

Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.

Leukemia. 2012 Apr;26(4):563-71. doi: 10.1038/leu.2011.314. Epub 2011 Nov 11.

Activated Protein C Resistance in Polycythemia Vera.

Turk J Haematol. 2001 Sep 5;18(3):157-64.

Clinical Spectrum and Complications of Polycythemia, in Patients presenting at Tertiary Care Centre at Goa.

J Assoc Physicians India. 2019 Oct;67(10):20-24.

Acute coronary artery bypass graft failure in a patient with polycythemia vera.

Asian Cardiovasc Thorac Ann. 2016 Feb;24(2):175-7. doi: 10.1177/0218492314550725. Epub 2014 Sep 4.

[Chinese expert consensus on the comprehensive management of thromboembolism in polycythemia vera].

Zhonghua Yi Xue Za Zhi. 2023 Feb 7;103(5):319-328. doi: 10.3760/cma.j.cn112137-20220708-01508.

Tissue plasminogen activator levels in different types of polycythemia.

Eur J Haematol. 1990 Jul;45(1):48-51. doi: 10.1111/j.1600-0609.1990.tb00414.x.

本文引用的文献

Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.

Blood. 2024 Apr 18;143(16):1646-1655. doi: 10.1182/blood.2023020232.

Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction.

Oncologist. 2023 Jul 5;28(7):555-564. doi: 10.1093/oncolo/oyad116.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

J Clin Oncol. 2023 Jul 1;41(19):3534-3544. doi: 10.1200/JCO.22.01935. Epub 2023 May 1.

JAK2 V617F allele burden in polycythemia vera: burden of proof.

Blood. 2023 Apr 20;141(16):1934-1942. doi: 10.1182/blood.2022017697.

Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists.

Res Pract Thromb Haemost. 2021 Sep 14;5(6):e12574. doi: 10.1002/rth2.12574. eCollection 2021 Aug.

A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.

Blood Adv. 2021 Jan 12;5(1):113-121. doi: 10.1182/bloodadvances.2020003628.

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms.

Ann Hematol. 2021 Aug;100(8):2015-2022. doi: 10.1007/s00277-020-04350-6. Epub 2020 Nov 20.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Lancet Haematol. 2020 Mar;7(3):e196-e208. doi: 10.1016/S2352-3026(19)30236-4. Epub 2020 Jan 31.

Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Blood Adv. 2019 Jun 11;3(11):1729-1737. doi: 10.1182/bloodadvances.2019000211.

Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera.

Blood Cancer J. 2018 Nov 26;8(12):124. doi: 10.1038/s41408-018-0161-9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献